Lupin has received approval from US Food and Drug Administration (USFDA) for its supplemental New Drug Application (sNDA) for usage of its antibiotic Solosec in adolescents for treatment of both bacterial vaginal infection in females and sexually transmitted infection, trichomoniasis. The USFDA has approved the company's sNDA to expand the use of Solosec in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and above.
The supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV. Solosec is an oral antibiotic used to treat bacterial vaginosis in adult women and also in treating Trichomoniasis, a common sexually transmitted infection (STI), in adults.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: